Ligand Pharmaceuticals Incorporated
General ticker "LGND" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.5B (TTM average)
Ligand Pharmaceuticals Incorporated follows the US Stock Market performance with the rate: 61.6%.
Estimated limits based on current volatility of 2.7%: low 220.95$, high 233.10$
Factors to consider:
- Total employees count: 68 (+17.2%) as of 2024
- Top business risk factors: Operational and conduct risks, Supply chain disruptions, Partnership program failure, Economic downturns and volatility, Regulatory and compliance
- Current price 15.0% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [136.29$, 201.52$]
- 2026-12-31 to 2027-12-31 estimated range: [131.65$, 197.42$]
Financial Metrics affecting the LGND estimates:
- Negative: with PPE of 24.3 at the end of fiscal year the price was high
- Positive: 7.68 < Operating profit margin, % of 17.61
- Positive: 0.07 < Operating cash flow per share per price, % of 1.30
- Positive: Return on assets ratio (scaled to [-100,100]) of 7.39 > 6.12
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -4.14 <= -0.75
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term LGND quotes
Long-term LGND plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $133.44MM | $152.08MM | $268.09MM |
| Operating Expenses | $121.49MM | $174.68MM | $220.89MM |
| Operating Income | $11.94MM | $-22.61MM | $47.20MM |
| Non-Operating Income | $51.72MM | $25.12MM | $111.76MM |
| Interest Expense | $0.66MM | $3.04MM | $0.00MM |
| R&D Expense | $24.54MM | $21.43MM | $81.18MM |
| Income(Loss) | $63.66MM | $2.52MM | $158.96MM |
| Taxes | $9.84MM | $6.55MM | $34.51MM |
| Other Income(Loss) | $-1.67MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $50.49MM | $-4.03MM | $124.45MM |
| Stockholders Equity | $700.91MM | $830.44MM | $1,017.21MM |
| Inventory | $23.97MM | $14.11MM | $9.13MM |
| Assets | $787.22MM | $941.77MM | $1,560.64MM |
| Operating Cash Flow | $49.58MM | $97.05MM | $49.36MM |
| Capital expenditure | $53.85MM | $19.64MM | $0.45MM |
| Investing Cash Flow | $-11.68MM | $-143.66MM | $-377.32MM |
| Financing Cash Flow | $-59.95MM | $97.14MM | $428.22MM |
| Earnings Per Share** | $2.92 | $-0.22 | $6.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.